Search - tctmd.com

Displaying 1 - 12 of 12

Sort: Relevancy | Date

DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years

News Conference News VIVA 2024

DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years

November 11, 2024

FDA Approves DETOUR for Percutaneous Bypass in Long, Complex SFA

News Conference News LINC 2023

FDA Approves DETOUR for Percutaneous Bypass in Long, Complex SFA

June 08, 2023

FDA: Endologix AAA Grafts Get New Labeling That Addresses Endoleak Potential

News Daily News

FDA: Endologix AAA Grafts Get New Labeling That Addresses Endoleak Potential

December 06, 2022

FDA Safety Communication Updates Stance on Endologix AAA Grafts

News Daily News

FDA Safety Communication Updates Stance on Endologix AAA Grafts

January 13, 2022

FDA Reminder: Yearly, Lifelong Surveillance Needed for Endologix AAA Grafts

News Daily News

FDA Reminder: Yearly, Lifelong Surveillance Needed for Endologix AAA Grafts

December 04, 2020

FDA: New Concerns Surface With Endologix Grafts for AAA

News Daily News

FDA: New Concerns Surface With Endologix Grafts for AAA

October 28, 2019

FDA: All AFX Endovascular AAA Systems Now Under Class I Recall

News Daily News

FDA: All AFX Endovascular AAA Systems Now Under Class I Recall

October 16, 2018

News Industry News

Endologix Reports Positive 1-Year Results from the Ovation® LUCY Study

July 09, 2018

FDA Identifies Culprit in Endovascular Graft Type III Endoleaks

News Daily News

FDA Identifies Culprit in Endovascular Graft Type III Endoleaks

June 19, 2018

EVAR Outcomes Equivalent Between Men and Women, Registries Show

News Conference News VIVA 2017

EVAR Outcomes Equivalent Between Men and Women, Registries Show

September 14, 2017

News Daily News

在医疗保险人口中，EVAR的早期生存优势在3年后失去

July 23, 2015

News Daily News

En la Población de Medicare, el Beneficio Precoz sobre la Supervivencia que ofrece EVAR Desaparece a los 3 Años

July 23, 2015

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.